Navigation Links
Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2007 Financial Results
Date:11/12/2007

milestones and reimbursements earned through the company's Wyeth

collaboration

-- Total operating expenses - $55 million to $60 million

-- Operating cash requirements - $28 million to $32 million

Conference Call Details

Trubion will host a conference call and webcast to discuss its third quarter 2007 financial results. The call will be held today at 2 p.m. Pacific Time; 5 p.m. Eastern Time. The live event will be available from Trubion's Web site at http://investors.trubion.com/events.cfm, or by calling 1-888-208-1386 or 913-981-5593. A replay of the discussion will be available beginning later today from Trubion's Web site or by calling 1-888-203-1112 or 1-719-457-0820, and entering 4262106. The webcast replay will be available in the events section of Trubion's Web site.

About Trubion

Trubion is a biopharmaceutical company creating a pipeline of product candidates to treat autoimmune disease and cancer. The company's product candidates are novel proteins known as single-chain polypeptides and are designed using its SMIP custom drug assembly technology. In less than 24 months, the company designed, developed and submitted to the FDA an Investigational New Drug (IND) application for its lead product candidate, TRU-015, which has completed a Phase IIb clinical trial for the treatment of rheumatoid arthritis. In December 2005, the company entered into a collaboration agreement with Wyeth for the development and worldwide commercialization of certain therapeutics, including TRU-015. In addition, Trubion's TRU-016 program targets CD37, an antigen present on B cells, for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukemia. The company filed an IND for TRU-016 in the fourth quarter of 2007. Trubion currently retains all development and commercialization rights for the TRU-016 program. For additional information visit

SOURCE Trubion Pharmaceuticals Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Trubion Pharmaceuticals to Present at Upcoming Investor Conferences
2. Trubion Pharmaceuticals Announces Upcoming Presentations at American College of Rheumatology Annual Scientific Meeting
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
7. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
8. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
9. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
10. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
11. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... His Majesty Willem-Alexander, King of the Netherlands ... His Majesty Willem-Alexander, King of the Netherlands, has announced ... POET-DSM Advanced Biofuels’ Project LIBERTY cellulosic ethanol plant in ... will take part in the Grand Opening Ceremony to ... p.m. and tour the plant. POET-DSM is a joint ...
(Date:8/21/2014)... YORK , Aug. 21, 2014 Mathematic studies ... Harvard University , and funded by the Jeffrey ... cells within tumors can be visually identified for elimination. These ... growth. The study, which shows a topological map of what ... time in cancer research, for while tumor cells can be ...
(Date:8/21/2014)... 2014 Pursuit Solutions ( http://www.pursuit-solutions.com ... and services for Life Sciences sales and marketing ... of New Commercial Sales Models” by Peter Robinson, ... The article examines some innovative models used to ... tested in the pharmaceutical market. Robinson grades the ...
(Date:8/21/2014)... 2014 On Wednesday of last week RENU ... Redox Signaling molecules, became available for purchase in Australia and ... way that RENU 28 works is, if you think about ... the rate of cellular renewal within your body. If you ... that rate of cellular renewal. What RENU 28 does is ...
Breaking Biology Technology:His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 2His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 3Science Power Jeffrey Epstein and Harvard University Fund Project to Visually Stop Tumor Growth 2Pursuit's Peter Robinson Publishes "Grading Pharma's Use of New Commercial Sales Models" 2RENU 28 Skin Care Now Available in Australia and New Zealand 2
... DIEGO, Sept. 2 Halozyme Therapeutics,Inc. (Nasdaq: ... and,commercializing products targeting the extracellular matrix, today,announced ... President,Research, Michael J. LaBarre, PhD, Vice President, ... Legal., "Halozyme is committed to attracting, ...
... licenses ... STAMFORD, Conn., Sept. 2 Purdue Pharma L.P. ... to end the OxyContin(R) (oxycodone HCl controlled-release) Tablets,patent infringement ... the Southern District of New York., According to ...
... Biotech Inc.,("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that ... the Company is initiating a U.S.,Phase 2 ... in,combination with paclitaxel and carboplatin in patients ... or EGFR-activated tumours. The Principal,Investigator is Dr. ...
Cached Biology Technology:Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives 2Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives 3Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives 4Purdue Pharma L.P. Announces Resolution of OxyContin(R) Patent Lawsuit with Mallinckrodt Inc. 2Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours 2Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours 3Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours 4
(Date:8/21/2014)... tube connectors, designed by an international standards process, will ... According to an invited review published in the OnlineFirst ... NCP ), the official journal of the American Society ... will greatly reduce the occurrence of misconnection that can ... connectors, which are used to join medical devices, components, ...
(Date:8/21/2014)... the pancreas digesting itself resulting in severe abdominal pain, ... around 20,000 patients are diagnosed with the disease resulting ... treatment is restricted to intravenous fluid and nutritional support. ... Life Sciences, who led the research, said "The major ... stones and excessive alcohol intake combined with a high ...
(Date:8/20/2014)... University of Tennessee, Knoxville, research finds life can persist ... professor was part of a team that examined waters ... Antarctic ice sheet and found the extreme environment supports ... by Jill Mikucki and her colleagues has implications for ... in the solar system. The findings are published in ...
Breaking Biology News(10 mins):New feeding tube connectors will improve patient safety 2Insulin offers new hope for the treatment of acute pancreatitis 2University of Tennessee research uncovers subglacial life beneath Antarctic ice sheet 2
... and Canadian research team surveying mercury contamination in fish ... Canada has identified five "hotspots" where concentrations of the ... The team focused on levels of the potent neurotoxin ... took into account contamination in other fish, birds, and ...
... of thousands of heart patients to have high-tech devices implanted ... expensive devices are designed to shock damaged hearts back into ... 300,000 Americans each year. , But a new study finds ... ICDs, a large number won't -- and a simple heart-rhythm ...
... from grain, but the U.S. Department of Energy (DOE) would ... alternatives, such as paper pulp, sawdust, straw and grain hulls. ... by analyzing the DNA of a bacterium that can break ... also found in forestry by-products (including paper) and waste feedstocks. ...
Cached Biology News:Hotspots of mercury contamination identified in eastern North America 2Are one-third of costly implanted heart devices unnecessary? New study suggests yes 2Are one-third of costly implanted heart devices unnecessary? New study suggests yes 3McBride shows DNA detective work with paper-eating bacteria that 'glide' 2McBride shows DNA detective work with paper-eating bacteria that 'glide' 3
... Kilo-Sequencing is designed to aid sequence analysis ... multiple cloning sites (MCS) of M13 phage ... vectors (pUC18/19). The kit is used to ... DNA, thereby progressively moving the primer binding ...
Applications: Immunohistochemistry, ISH, FISH, CISH....
Attachments: Clip bar for tubes 10 to 19 mm in diameter Overall Dimension Height IC: 6 (15.2) Overall Dimension Length IC: 18.5 (46.9) Overall Dimension Width IC: 4 (10.2)...
Request Info...
Biology Products: